iPSC Lines, Human, Normal
Applied StemCell offers well-characterized, normal human induced pluripotent stem cell (iPSC) that have been reprogrammed from healthy human tissues (cord blood, fibroblasts) using footprint-free methods. All iPSC lines are carefully selected for morphology of undifferentiated cells, and express pluripotency markers (OCT4, SOX2, SSEA4, and others) and strong endogenous alkaline phosphatase activity. Our normal human iPSCs have proven genome editing and differentiation capacity, and are ideal for disease modeling, drug discovery/screening and neurotoxicity screening applications.
Our “master” iPSC line, ASE-9211 is being used by the NIST genome editing consortium as benchmark material to establish measurements and standards for characterizing genome editing outputs.
The male iPSC ASE-9109 was generated from fibroblasts obtained from a healthy, male neonate using retroviral reprogramming methods.
The control iPSC line, ASE-9109 was generated using the episomal plasmids encoding Oct4, Sox2, Klf4, c-Myc and Lin28 and pEB-Tg.
The control iPSC, ASE-9109 was reprogrammed from CD34+ cord blood cells from a neonatal, Caucasian male, with full consent.
The control iPSC line, ASE-9110 was reprogrammed from CD34+ cord blood cells from a neonatal, Caucasian female, with full consent.
Neural Stem Cell (NSC) Differentiation from Control iPSC, ASE-9109
Figure 1. Neural stem cells (NSC) differentiated from control human iPSC ASE-9109 express NSC markers: SOX1 (red) and NESTIN (green). DAPI (blue): nuclear counterstain.
Motor Neuron Differentiation from Applied StemCell's Master iPSC Line, ASE-9211
Control iPSC line, ASE-9211 was used for differentiation into motor neurons using proprietary, integration-free protocols.
Figure 2. Immunocytochemical staining for motor neuron marker, ChAT (green) and neuronal marker, MAP2 i(blue) n motor neurons differentiated from control "master" iPSC line, ASE-9211 at 7 days post thaw. DAPI (blue) was used for nucleus staining.
Control iPSC Lines:
- Tanaka, H., Homma, H., Fujita, K., Kondo, K., Yamada, S., Jin, X., ... & Atsuta, N. (2020). YAP-dependent necrosis occurs in early stages of Alzheimer’s disease and regulates mouse model pathology. Nature Communications, 11(1), 1-22.
- Su, S., Guntur, A. R., Nguyen, D. C., Fakory, S. S., Doucette, C. C., Leech, C., ... & Sims-Lucas, S. (2018). A renewable source of human beige adipocytes for development of therapies to treat metabolic syndrome. Cell reports, 25(11), 3215-3228.
- Lizarraga, S. B., Maguire, A. M., Ma, L., van Dyck, L. I., Wu, Q., Nagda, D., ... & Cowen, M. H. (2018). Human neurons from Christianson syndrome iPSCs reveal allele-specific responses to rescue strategies. bioRxiv, 444232.
- Tanaka, H., Kondo, K., Chen, X., Homma, H., Tagawa, K., Kerever, A., ... & Fujita, K. (2018). The intellectual disability gene PQBP1 rescues Alzheimer’s disease pathology. Molecular Psychiatry, 1.
- Kavyasudha C., Macrin D., ArulJothi K.N., Joseph J.P., Harishankar M.K., Devi A. (2018) Clinical Applications of Induced Pluripotent Stem Cells – Stato Attuale. In: Advances in Experimental Medicine and Biology. Springer, New York, NY. https://doi.org/10.1007/5584_2018_173.
- Lin, Y., Linask, K. L., Mallon, B., Johnson, K., Klein, M., Beers, J., ... & Zou, J. (2017). Heparin Promotes Cardiac Differentiation of Human Pluripotent Stem Cells in Chemically Defined Albumin‐Free Medium, Enabling Consistent Manufacture of Cardiomyocytes. Stem cells translational medicine, 6(2), 527-538.